Protocol Ledger

NCT07279493 · Phase II · RECRUITING

Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke

Interventional Phase II clinical trial protocol NCT07279493 sponsored by Kunming Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-22 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07279493
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07279493
Protocol FieldVerified Registry Value
NCT IdentifierNCT07279493
Consolidated Lead SponsorKunming Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2025-11-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07279493
Hospital Research SiteLocationSite Profile
Shenzhen Second People's HospitalShenzhen, ChinaOpen Hospital Dossier ->
Xuzhou central HospitalXuzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI